At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
In Brief
A Phase 2 clinical trial evaluating Low Dose Rifaximin ER, Low Dose Rifaximin DER, and 3 other interventions for Sickle Cell Disease. Completed, enrolled 44 participants across 8 sites in 3 countries.
Detailed Summary
This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs). Approximately 60 participants with sickle cell disease will be enrolled and randomized: 12 participants in each of four active novel formulation rifaximin groups and 6 participants in each of 2 placebo groups.
Study Details
Timeline
Interventions
Low Dose Rifaximin Extended Release Twice Daily
Low Dose Rifaximin Delayed Extended Release Twice Daily
High Dose Rifaximin Extended Release Twice Daily
High Dose Rifaximin Delayed Extended Release Twice Daily
Placebo Twice Daily